NO20060540L - Matriks metallproteinase-inhibitorer - Google Patents
Matriks metallproteinase-inhibitorerInfo
- Publication number
- NO20060540L NO20060540L NO20060540A NO20060540A NO20060540L NO 20060540 L NO20060540 L NO 20060540L NO 20060540 A NO20060540 A NO 20060540A NO 20060540 A NO20060540 A NO 20060540A NO 20060540 L NO20060540 L NO 20060540L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- alkylaryl
- cor
- optionally substituted
- bond
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 2
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000006168 tricyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Soft Magnetic Materials (AREA)
- Indole Compounds (AREA)
- Lubricants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
| PCT/EP2004/010319 WO2005026120A1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060540L true NO20060540L (no) | 2006-04-04 |
Family
ID=29227079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060540A NO20060540L (no) | 2003-09-13 | 2006-02-02 | Matriks metallproteinase-inhibitorer |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7601729B2 (enExample) |
| EP (3) | EP1663970B1 (enExample) |
| JP (3) | JP2007505081A (enExample) |
| KR (3) | KR20130079628A (enExample) |
| CN (1) | CN1849306B (enExample) |
| AT (2) | ATE502922T1 (enExample) |
| AU (1) | AU2004272280C1 (enExample) |
| BR (1) | BRPI0413791A (enExample) |
| CA (1) | CA2538315C (enExample) |
| CY (1) | CY1109400T1 (enExample) |
| DE (2) | DE602004031991D1 (enExample) |
| DK (1) | DK1663970T3 (enExample) |
| ES (2) | ES2362954T3 (enExample) |
| GB (1) | GB0321538D0 (enExample) |
| HR (1) | HRP20080668T3 (enExample) |
| IL (1) | IL173305A (enExample) |
| IS (2) | IS2622B (enExample) |
| MA (1) | MA28039A1 (enExample) |
| MX (1) | MXPA06002458A (enExample) |
| NO (1) | NO20060540L (enExample) |
| NZ (2) | NZ573479A (enExample) |
| PL (1) | PL1663970T3 (enExample) |
| PT (1) | PT1663970E (enExample) |
| RU (2) | RU2370488C2 (enExample) |
| SG (1) | SG145685A1 (enExample) |
| SI (1) | SI1663970T1 (enExample) |
| WO (1) | WO2005026120A1 (enExample) |
| ZA (1) | ZA200602070B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| DK1856063T3 (da) * | 2005-02-22 | 2012-03-26 | Ranbaxy Lab Ltd | 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme |
| AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
| BRPI0715231A2 (pt) * | 2006-08-22 | 2013-06-25 | Ranbaxy Lab Ltd | compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto |
| EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
| FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
| SG187654A1 (en) | 2010-07-30 | 2013-03-28 | Ranbaxy Lab Ltd | Matrix metalloproteinase inhibitors |
| JP2013540754A (ja) | 2010-09-24 | 2013-11-07 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
| US20160045463A1 (en) | 2012-11-28 | 2016-02-18 | Universidad De Salamanca | Use of metalloprotease inhibitors in the treatment of polycystic liver diseases |
| SG11201806416XA (en) | 2016-02-12 | 2018-08-30 | Astellas Pharma Inc | Tetrahydroisoquinoline derivatives |
| JP7143334B2 (ja) * | 2017-06-13 | 2022-09-28 | エシコン エルエルシー | 治癒を制御させる手術用ステープラ |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1995029901A1 (en) * | 1994-04-28 | 1995-11-09 | Uniroyal Chemical Company, Inc. | Fungicidal azole derivatives |
| HUP9900143A3 (en) * | 1995-12-06 | 2000-04-28 | Astra Pharmaceuticals Ltd King | Pharmaceutically useful 3-pyridil-compounds |
| NZ332334A (en) | 1996-04-19 | 2000-06-23 | Akzo Nobel Nv | Substituted benzylamines and their use for the treatment of depression and other neurologically related disorders |
| HRP970246B1 (en) * | 1996-05-15 | 2002-04-30 | Bayer Ag | Substituted oxobutric acids as matrix metalloprotease inhibitors |
| US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
| US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
| US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
| US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
| US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| CA2490819A1 (en) * | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| WO2004012663A2 (en) | 2002-08-01 | 2004-02-12 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| DE60330997D1 (de) * | 2002-11-19 | 2010-03-04 | Galderma Res & Dev | Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen |
| GB0312654D0 (en) | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0319069D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| DK1856063T3 (da) | 2005-02-22 | 2012-03-26 | Ranbaxy Lab Ltd | 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme |
| BRPI0715231A2 (pt) | 2006-08-22 | 2013-06-25 | Ranbaxy Lab Ltd | compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es not_active Expired - Lifetime
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Ceased
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Ceased
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 EP EP04765231A patent/EP1663970B1/en not_active Expired - Lifetime
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de not_active Expired - Lifetime
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 HR HR20080668T patent/HRP20080668T3/xx unknown
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en not_active Ceased
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de not_active Expired - Lifetime
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 EP EP08163972A patent/EP2042488B1/en not_active Expired - Lifetime
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es not_active Expired - Lifetime
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko not_active Ceased
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 EP EP10176905A patent/EP2295408A1/en not_active Withdrawn
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109400T1 (el) | Αναστολεις μεταλλοπρωτεϊνασης μητρας | |
| ATE362910T1 (de) | Matrix metalloprotease inhibitoren | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| NO20013254D0 (no) | Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| DK1010698T3 (da) | Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem | |
| TW200510357A (en) | Continuous process for the preparation of pesticides | |
| ATE239021T1 (de) | Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| EA200301079A1 (ru) | Терапевтическое средство по поводу повышенной чувствительности мочевого пузыря | |
| WO2002074764A3 (en) | Piperazine derivatives and their use as 5-ht1b ligands | |
| DK1188752T3 (da) | Fremgangsmåde til fremstilling af substitueret alkylaminderivat | |
| GB1183442A (enExample) | ||
| WO2005016868A3 (en) | Matrix metalloproteinase inhibitors | |
| PT955310E (pt) | Novos derivados do acido (3,4,7,8,9,10)-hexa-hidro-6,10-dioxo-6h-piridazino[1,2-a] [1,2]diazepina-1-carboxilico, seu metodo de preaparacaoe sua aplicacao na preparacao de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |